ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer Post author:admERY Post published:July 28, 2014 Post category:Newsroom ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing November 6, 2017 ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer June 5, 2012 ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 May 24, 2022
ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer June 5, 2012
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 May 24, 2022